Cenicriviroc

Drug Profile

Cenicriviroc

Alternative Names: CCR5/CCR2 antagonist; Cenicriviroc mesylate; CVC; TAK-652; TBR-652

Latest Information Update: 23 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator National Institute for Health Research; Takeda
  • Developer Dong-A ST; Imperial College of Science, Technology and Medicine; National Institute for Health Research; Tobira Therapeutics
  • Class Amides; Antifibrotics; Antineoplastics; Antiretrovirals; Imidazoles; Small molecules
  • Mechanism of Action CCR2 receptor antagonists; CCR5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-alcoholic steatohepatitis
  • Phase II HIV-1 infections; Non-alcoholic fatty liver disease; Primary sclerosing cholangitis
  • Preclinical Cancer; Cholestasis; Diabetic nephropathies; Graft-versus-host disease; Liver disorders

Most Recent Events

  • 19 Apr 2017 Pharmakinetic and adverse events data from a phase I trial in healthy volunteers presented at the International Liver Congress 2017 (ILC-2017)
  • 18 Apr 2017 Allergan in collaboration with Novartis plans a phase IIb trial for Non-alcoholic steatohepatitis (Combination therapy)
  • 04 Apr 2017 Phase-III clinical trials in Non-alcoholic steatohepatitis in USA and Puerto Rico (PO) (NCT03028740)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top